BG9928 in Subjects With Hepatic Impairment

NCT00858156 | Completed Phase 1

• 1 other identifier: 161HI101
• Study Type: interventional
• Target: 23
• Locations: 1 country
• Sites: 2

Brief Summary

The primary objective of the study is to evaluate the effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment and in subjects with normal hepatic function.

Conditions

Hepatic Impairment

Keywords

Pharmacokinetics

Outcome Measures

Primary Outcomes (1)

• The comparative effect of hepatic function on the pharmacokinetics of a single oral dose of BG9928 in subjects with mild and moderate hepatic impairment as compared to subjects with normal hepatic function

  1 week post dose

Interventions

BG9928 DRUG

Oral 75 mg single dose

Eligibility Criteria

• Age: 18 Years - 75 Years
• Sex: all
• Healthy Volunteers: Yes
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Must be between the ages of 18 and 75, inclusive.
• Must have a Body Mass Index (BMI) between 19 kg/m2 and 36 kg/m2, inclusive.
• The following criteria apply only to subjects enrolled into Groups 1 and 2 (mild or moderate hepatic impairment):
• Must have stable hepatic disease (i.e., no change in disease status within the last 2 months as determined by the enrolling Investigator) with laboratory and clinical findings that support the diagnosis of hepatic impairment.
• Must have a total Child-Pugh score (Section 22, Appendix I) of 5-6 (mild), or 7-9 (moderate).
• Must be otherwise healthy as determined by the Investigator on the basis of pre-study physical examination, medical history, 12-lead ECG, vital signs, and clinical laboratory parameters. Subjects with controlled hypertension and those problems directly associated with the primary diagnosis of hepatic impairment may be included. Subjects with stable, mild, chronic concurrent diseases, such as degenerative joint disease, may be included.

You may not qualify if:

• History of an allergic reaction to any methylxanthine-containing compound.
• History of seizure within the past 10 years, or use of any medication for the suppression of seizures within the past 5 years.
• History of brain surgery, meningitis/encephalitis, penetrating head trauma, stroke, or transient ischemic attack within the past 6 months.
• History of active (within 6 months) drug or alcohol abuse, a positive drug screen (without a medically indicated rationale), or a positive alcohol breath test at Screening or on Day -2.
• History of Human Immunodeficiency Virus (HIV) antibody.
• Serious systemic infection (e.g., septicemia) within the 30 days prior to Day 1.
• Fever, with body temperature \>38oC, within the 48 hours prior to Day 1.
• Active bacterial or viral infection.

Sponsors & Collaborators

• Biogen: lead

Study Sites (2)

Unknown Facility

Miami, Florida, 33014, United States

Location

Unknown Facility

Orlando, Florida, 32809, United States

Location

MeSH Terms

Interventions

BG 9928

Study Officials

• Biogen Idec

  Biogen

  STUDY DIRECTOR

Study Design

• Study Type: interventional
• Phase: phase 1
• Allocation: NON RANDOMIZED
• Masking: NONE
• Intervention Model: PARALLEL
• Sponsor Type: INDUSTRY

Study Record Dates

• First Submitted: March 5, 2009
• First Posted: March 9, 2009
• Study Start: April 1, 2009
• Primary Completion: August 1, 2009
• Study Completion: August 1, 2009
• Last Updated: January 27, 2010

Record last verified: 2010-01

Locations

US (2)